Cargando…
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in part through suppression of the MYC oncogene and do...
Autores principales: | Wyce, Anastasia, Ganji, Gopinath, Smitheman, Kimberly N., Chung, Chun-wa, Korenchuk, Susan, Bai, Yuchen, Barbash, Olena, Le, BaoChau, Craggs, Peter D., McCabe, Michael T., Kennedy-Wilson, Karen M., Sanchez, Lydia V., Gosmini, Romain L., Parr, Nigel, McHugh, Charles F., Dhanak, Dashyant, Prinjha, Rab K., Auger, Kurt R., Tummino, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751846/ https://www.ncbi.nlm.nih.gov/pubmed/24009722 http://dx.doi.org/10.1371/journal.pone.0072967 |
Ejemplares similares
-
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013) -
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
por: Wyce, Anastasia, et al.
Publicado: (2018) -
BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018) -
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
por: Mazur, Pawel K., et al.
Publicado: (2014) -
Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019)